治疗前多参数MRI预测乳腺癌新辅助化疗后肿瘤退缩模式
该研究回顾性纳入420例接受新辅助化疗并手术的乳腺癌患者,以手术病理为金标准将退缩模式分为向心性与非向心性,结合治疗前MRI形态与动力学特征及临床病理特征建立预测模型,七种模型AUC为0.669-0.740,决策树最高0.740,内部验证乐观校正AUC为0.592-0.684。
要点
- 治疗前MRI联合临床病理特征有助于预测乳腺癌新辅助化疗后的肿瘤退缩模式。
- 决策树模型预测效能最高,AUC为0.740,但内部验证后降至0.684。
- 预测向心性退缩可辅助筛选适合降级手术的患者并调整治疗策略。
核心结论
- 联合治疗前MRI与临床病理特征的预测模型可用于预测乳腺癌新辅助化疗后的肿瘤退缩模式,辅助筛选可从新辅助化疗中获益以降级乳腺手术及调整治疗策略的患者。
研究设计与样本
- 回顾性研究,纳入2012年2月至2020年8月在本院接受新辅助化疗并接受确定性手术的420例乳腺癌患者。
- 以手术标本病理所见为金标准,将肿瘤退缩模式分为向心性与非向心性。
- 分析MRI形态学与动力学特征,采用单因素及多因素分析筛选预测退缩模式的关键临床病理与MRI特征。
- 采用逻辑回归与六种机器学习方法构建预测模型,以受试者工作特征曲线评估效能。
诊断标准与关键数值
- 两个临床病理变量与三个MRI特征被选为独立预测因子用于构建预测模型。
- 七种预测模型的表观AUC范围为0.669-0.740。
- 逻辑回归模型AUC为0.708(95%CI:0.658-0.759)。
- 决策树模型AUC最高,为0.740(95%CI:0.691-0.787)。
- 内部验证中七种模型的乐观校正AUC范围为0.592-0.684;逻辑回归模型与各机器学习模型AUC间无显著差异。
临床应用与阅片要点
- 治疗前多参数MRI的形态与动力学特征结合临床病理信息可用于预测新辅助化疗后退缩模式,辅助术前规划。
- 预测为向心性退缩的患者可能适合降级乳腺手术,非向心性退缩者需调整治疗策略。
- 模型内部验证后效能下降,提示外部推广前需谨慎解读预测概率。
局限性
- 回顾性单中心研究,仅进行内部验证,未报告外部验证结果。
- 原文未报告具体的临床病理变量与MRI特征名称及其回归系数或阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To develop an easy-to-use model by combining pretreatment MRI and clinicopathologic features for early prediction of tumor regression pattern to neoadjuvant chemotherapy (NAC) in breast cancer.
MATERIALS AND METHODS: We retrospectively analyzed 420 patients who received NAC and underwent definitive surgery in our hospital from February 2012 to August 2020. Pathologic findings of surgical specimens were used as the gold standard to classify tumor regression patterns into concentric and non-concentric shrinkage. Morphologic and kinetic MRI features were both analyzed. Univariable and multivariable analyses were performed to select the key clinicopathologic and MRI features for pretreatment prediction of regression pattern. Logistic regression and six machine learning methods were used to construct prediction models, and their performance were evaluated with receiver operating characteristic curve.
RESULTS: Two clinicopathologic variables and three MRI features were selected as independent predictors to construct prediction models. The apparent area under the curve (AUC) of seven prediction models were in the range of 0.669-0.740. The logistic regression model yielded an AUC of 0.708 (95% confidence interval [CI]: 0.658-0.759), and the decision tree model achieved the highest AUC of 0.740 (95% CI: 0.691-0.787). For internal validation, the optimism-corrected AUCs of seven models were in the range of 0.592-0.684. There was no significant difference between the AUCs of the logistic regression model and that of each machine learning model.
CONCLUSION: Prediction models combining pretreatment MRI and clinicopathologic features are useful for predicting tumor regression pattern in breast cancer, which can assist to select patients who can benefit from NAC for de-escalation of breast surgery and modify treatment strategy.
引用
- Liu, Huang, Chen, et al. Use of Pretreatment Multiparametric MRI to Predict Tumor Regression Pattern to Neoadjuvant Chemotherapy in Breast Cancer. Acad Radiol. 2023. PMID: 37019697. doi:10.1016/j.acra.2023.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。